ArticleTranslational andrology and urology2025
Association between tacrolimus intrapatient variability and clinical outcomes in kidney transplantation: a retrospective cohort study.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype-Guided Tacrolimus Dosing.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In therapeutic drug monitoring (TDM) of tacrolimus, trough concentration is the most commonly used monitoring indicator, which has limited association with clinical outcomes. Intrapatient variability (IPV), as a novel monitoring marker for describing the extent of fluctuation in blood concentration, holds promise as an additional monitoring tool. The effect of tacrolimus IPV on Chinese kidney transplantation outcomes is unclear, and the aim of this study is to explore the association between IPV and poorer outcomes of Chinese kidney transplantation recipients and to discuss the influence of genotype. Methods: A total of 152 patients were enrolled, whose kidney transplantation operations were carried out from January 2015 to February 2022 in Peking University Third Hospital. IPV was calculated by coefficient of variation (CV) of tacrolimus whole blood concentrations during 6 and 12 months after transplantation. Clinical outcomes were analyzed between patients with high IPV and low IPV, including graft loss, acute rejection (AR), elevated serum creatinine (Scr), infection, hemogram abnormality and electrolyte disturbance. Moreover, the associations were compared according to different genotypes. Results: High IPV was associated with AR [hazard ratio (HR) =3.420; 95% confidence interval (CI): 1.142-10.245], hyperuricemia, and hypocalcemia (P<0.05). In cytochrome P450 (CYP)3A5 nonexpressers, high IPV was associated with graft loss, elevated Scr, hyperuricemia, hypocalcemia, hypomagnesemia and leukopenia (P<0.05), whereas no significant association was detected in Conclusions: IPV is associated with clinical outcomes such as AR in Chinese kidney transplantation recipients. More attention should be paid to the association between high IPV and adverse outcomes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.